medigraphic.com
ISSN 2078-7162 (Print)

2016, Number 1

<< Back Next >>

Rev Cub de Med Fis y Rehab 2016; 8 (1)

Biomarkers and some aspects of treatment in multiple sclerosis

Arias CAJ, González RJL

Language: Spanish
References: 21
Page: 111-124
PDF size: 104.79 Kb.


ABSTRACT

Introduction: multiple sclerosis is an inflammatory disease of the central nervous system of probable autoimmune origin and unknown cause.
Development: recently we have developed a number of biomarkers that allow more accurate understanding of the pathogenesis of the disease which facilitates better diagnosis and establish a better prognosis and to evaluate more effectively the treatment to patients affected indicated. Has conducted a review of these issues allowing argue that remains very important to the realization of nuclear magnetic resonance but other markers that are proving to be effective among which we can mention the neurofilament and optical coherence tomography are added. Novel criteria are also mentioned as the most effective therapy with that account globally for these patients literature review was conducted in Medline, Cochrane Library and Dynamed of the Evidence-Based Medicine, Virtual Health Library of Bireme and EBSCO from September 2010 to October 2014.
Conclusions: multiple sclerosis is the most common cause of neurological disorders in young adults and is the most common form of the disease by altering central nervous system myelin. Currently there are major advances in the identification of biomarkers that will surely help further more general knowledge of the disease and thus the diagnosis, prognosis and evaluation of best treatment.


REFERENCES

  1. Fernández, O; Arroyo-González R. Biomarcadores en esclerosis múltiple. Rev Española Neurol 2013:56(7):375-90.

  2. Fernández, O, Martin, R. Biomarcadores en la esclerosis múltiple: 2014. Rev Española Neurol 2014:58:553-70.

  3. Trip SA, Schlottmann PG, Jones SJ, Altmann DR, Garway-Heath DF, Thompson AJ, et al. Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis. Ann Neurol. 2005;58:383-91.

  4. Brandson, C. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther, 2001;69:89-95.

  5. Kostulas VK. Oligoclonal IgG bands in cerebrospinal fluid. Principles for demonstration and interpretation based on findings in 1114 neurological patients. Arch Neurol, 1987;44:1041-4.

  6. McLean BN, Thompson EJ. A study of immunoglobulin G in the cerebrospinal fluid of 1007 patients with suspected neurological disease using isoelectric focusing and the Log IgG-Index. A comparison and diagnostic applications. Brain, 1990;113:1269-89.

  7. Brandt AU, Zimmermann H. Patterns of retinal damage facilitatedifferential diagnosis between Susac syndrome and MS. PLoS One, 2012;7:e38741.

  8. Trip et al. Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis. Ann Neurol 2005;58:383-91

  9. McLean BN, Thompson EJ. A study of immunoglobulin G in the cerebrospinal fluid of 1007 patients with suspected neurological disease using isoelectric focusing and the Log IgG-Index. A comparison and diagnostic applications. Brain, 1990;113:1269-89.

  10. López-Méndez P, Montalban, X. Adhesión terapéutica a tratamiento inmunomodulador de pacientes con esclerosis múltiple. Rev Española Neurol 2013;(1):8-12.

  11. Fernández, O; Grupo Post-ECTRIMS. Revisión de las novedades presentadas en el XXVII Congreso del Comité Europeo para el tratamiento e investigación en esclerosis múltiple (ECTRIMS) (I). Rev Española Neurol 2013;57(5):217-229.

  12. Fernández, O, Grupo Post-ECTRIMS. Revisión de las novedades presentadas en el XXVII Congreso del Comité Europeo para el Tratamiento e Investigación en Esclerosis Múltiple (ECTRIMS) (II). Rev Española Neurol 2012;54(7):734-49.

  13. García-Merino J, Sánchez, A. Mecanismos básicos de acción del fingolimod en relación con la esclerosis múltiple. Rev Española Neurol 2012:55(1):31-7.

  14. Cervera, C. Infecciones y fingolimod. Rev Española Neurol 2012;55(4):227-37.

  15. Oreja-Guevara, C. Tratamiento de la espasticidad en la esclerosis múltiple: nuevas perspectivas con el uso de cannabinoides. Rev Española Neurol. 2012;55(7):421-30.

  16. Oreja-Guevara, C, Montalban, X. Documento de consenso sobre la espasticidad en pacientes con esclerosis múltiple. Rev Española Neurol 2013;57(8):359-73.

  17. Abad, P, Rivera, V, Grupo de Estudio de Esclerosis Múltiple de Latinoamérica (LACTRIMS. E) Rev Española Neurol. 2013;55(12):737-48.

  18. Olascoaga, J. Calidad de vida y esclerosis múltiple. Rev Española Neurol 2010;51:279-88.

  19. Bermejo, P, Oreja-Guevara, C. El dolor en la esclerosis múltiple: prevalencia, mecanismos, tipos y tratamiento. Rev Española Neurol 2010;50(2):101-8.

  20. López-Méndez, P, Jordi R. Adhesión terapéutica a tratamiento inmunomodulador de pacientes con esclerosis múltiple. Rev Española Neurol 2013;56:8-12.

  21. Terapeutical guide for multiple esclerosis. ECTRIMS, Nov. 2013. Arch Soc Esp Oftalmol. 2010:85(5) may.




2020     |     www.medigraphic.com